Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

BMC Public Health

Table 4 Insulin use in OAD plus insulin group, by insulin treatment duration

Insulin treatment duration (yrs)	n (%)^a	Prandial, n (%)^b	Basal, n (%)^b	Basal-bolus, n (%)^b	Premixes, n (%)^b	Others, n (%)^b
<1	21,145	1987	3376	1623	13,825	334
<1	(26.33)	(9.40)	(15.97)	(7.68)	(65.37)	(1.58)
≥1-5	27,617	2171	4992	1711	18,334	409
≥1-5	(34.39)	(7.86)	(18.08)	(6.20)	(66.38)	(1.48)
≥5-10	18,504	1198	3148	1561	12,280	317
≥5-10	(23.04)	(6.47)	(17.01)	(8.44)	(66.37)	(1.71)
≥10	13,042 (16.24)	834 (6.39)	2,223 (17.04)	1471 (11.28)	8204 (62.91)	310 (2.38)
Total^c	80,308	6190	13,739	6366	52,643	1370
P value^d		<0.0001	NS	NS	NS	NS

^aPercentage of patients among the full population; ^bPercentage of patients among the patients with particular insulin treatment duration; ^cData on diabetes duration were missing for 665 patients using insulin therapy; ^dChi-square test was used to compare the percentage of patients in different insulin regimens by insulin treatment duration.
NS = not significant.

ISSN: 1471-2458